Endo International plc (ENDPQ)

Market Cap	141.13K
Revenue (ttm)	2.01B
Net Income (ttm)	-2.45B
Shares Out	235.22M
EPS (ttm)	-10.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	618,662
Open	0.0006
Previous Close	0.0006
Day's Range	0.0006 - 0.0006
52-Week Range	0.0001 - 0.0800
Beta	0.80
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 27, 2023

About ENDPQ

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren's contracture and Peyronie's disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 25, 1996
• Employees: 2,931
• Stock Exchange: OTCMKTS
• Ticker Symbol: ENDPQ

Financial Performance

In 2023, ENDPQ's revenue was $2.01 billion, a decrease of -13.25% compared to the previous year's $2.32 billion. Losses were -$2.45 billion, -15.80% less than in 2022.